Evolent Health price target lowered to $12 from $18 at Oppenheimer

Oppenheimer lowered the firm’s price target on Evolent Health (EVH) to $12 from $18 and keeps an Outperform rating on the shares following quarterly results. Management provided visibility into 2026 revenue of $2.5B, which reflects $550M of new contract impact. Though the company continues to boast an attractive pipeline of growth, the near-term outlook remains subjected to the uncertainty around Medicare Advantage and the ACA, adds Oppenheimer.